70 results about "Immune reaction" patented technology

The present invention includes novel compositions and methods for treating comprising a compound with the Formula I:wherein n=0, 1, 2, 3, 4, or 5; X=NH or O or S; Y=phenyl, or a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R=H, C(O)R2, SO2R2; R1=H, C(O)R2, SO2R2; R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4; R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl, and Z=NH, or O, or none, and optionally wherein both X and Z are not both S, and wherein the amount of the compound is selected to either inhibit or activate the immune response.

The invention provides an influenza virus that demonstrates enhanced growth in Vero cells. The influenza virus includes PA, NP, and NS gene segments having selected nucleotides and encoding proteins having amino acid sequences with selected amino acids. The invention also provides a pharmaceutical formulation containing the influenza virus, as well as a method of eliciting an immune response in a mammal by administering the influenza virus to the mammal, and a method for generating the influenza virus.

This invention relates to a self-adjuvanted biomimetic lipid nanoparticle, its microfluidic assembly method, and its anti-tumor applications. The self-adjuvanted biomimetic lipid nanoparticle has a structure in which an activated dendritic cell membrane (ADCM) is coated on the surface of a lipid nanoparticle (LNP) loaded with mRNA. The advancements of this invention compared to traditional LNPs are: the self-adjuvanted biomimetic lipid nanoparticle (ADCM-LNP) exhibits a faster cellular uptake rate and higher transfection efficiency, thereby inducing a strong Th1-type immune response and a potent CTL-mediated tumor-killing effect. In vivo biodistribution studies have shown that this system exhibits significant spleen-targeting (splenic tropism) and demonstrates excellent therapeutic efficacy in a HER2-positive breast cancer model.

Described herein are multicistronic expression systems that encode chimeric proteins, specifically membrane-cleavable chimeric systems and chimeric antigen receptors for administration in combination with the cytokine IL2 for treating a subject having cancer. Also described herein are nucleic acids, cells, and methods directed to the same. Also described herein are methods of stimulating a cell-mediated immune response to a tumor, reducing tumor volume, or providing an anti-tumor immunity in a human subject in need thereof, the methods comprise administering to a subject multiple administrations of an immunoresponsive cell encoding a controlled release cytokine.

This provides methods for treating coronavirus disease 2019 (COVID-19). [Solution] This disclosure provides a chimeric adenovirus vector comprising nucleic acids encoding coronavirus disease 2019 (COVID-19) protein and an adjuvant, and a method of using the vector to induce an immune response to the SARS-CoV-2 protein for the purpose of treating COVID-19.

This invention provides a combination therapy method to increase the effectiveness of cancer immunotherapy. [Solution] The present invention provides a combination therapy using bosentan and a checkpoint inhibitor that is effective in treating cancer in a target or inhibiting the proliferation of tumor cells, and / or can induce, enhance, or prolong an immune response against tumor cells. The effectiveness of cancer immunotherapy depends on whether T cells can migrate to the tumor, travel to locations adjacent to malignant cells, recognize them, and kill them.

The present invention is directed to a personalized in vitro immune response simulation system, including: a plurality of containers, each container including a culture of tissue-specific cells and endothelial cells in fluid contact with the tissue-specific cells; a liquid medium comprising at least about 25% serum or serum replacement (SR); immune cells suspended in the liquid medium; and a linkage system establishing fluidic coupling between the plurality of containers, allowing the liquid medium to flow through the linkage system, wherein the system is an isogenic system. The present invention further provides methods for preparation of such a system, and for uses thereof.

The invention relates to a Pseudomonas plecoglossicida pldB gene deletion mutant strain and a preparation method and application thereof, and belongs to the technical field of microorganisms and the field of algae preservation, the pldB gene of the mutant strain is deleted or inactivated, the nucleotide sequence of the pldB gene is shown as SEQ ID NO: 1, and the GenBank accession number of the Pseudomonas plecoglossicida is CP031146.1. The virulence of the mutant strain is obviously reduced compared with that of a wild strain of pseudomonas plecoglossicida; the strain can induce appropriate immune response of a host and up-regulate expression of anti-inflammatory factors, is beneficial to relieving immune pathological injury, has good attenuated live vaccine potential, and provides a brand new vaccine candidate strain for prevention and control of the visceral white-spot disease of the large yellow croaker.

This invention provides an immunoassay method comprising the following steps: S1: performing two parallel immunoassays on a sample containing the target molecule, recording the results of the two parallel immunoassays as the first and second values, respectively; S2: calculating the ratio of the first value to the second value; S3: determining the concentration of the target molecule in the sample. The assay method of this invention can solve the problem of HOOK effect samples, and the method is not limited by the detection range, capable of directly measuring up to 10... 6 High sample concentrations at the ng / ml level; good repeatability and fast detection speed.

The application discloses an LDH-based vaccine adjuvant and a preparation method and application thereof, and belongs to the technical field of aluminum adjuvant preparation of vaccines, and the preparation method comprises the following steps: mixing at least one of soluble magnesium salt, soluble zinc salt, soluble manganese salt and soluble calcium salt with soluble aluminum salt, and then performing a co-precipitation reaction with a sodium hydroxide aqueous solution in a colloid mill device, and performing crystallization to obtain LDH nanosheets; dispersing the LDH nanosheets in a PBS solution, adding a hepatitis B surface antigen molecule drug, uniformly mixing, and then performing centrifugation to obtain the LDH-based vaccine adjuvant. The LDH-based vaccine adjuvant can significantly promote the maturation of DC cells and the activation of T cells, and the total IgG level reflects the overall humoral immune response intensity of the body to vaccines or pathogens; the LDH-based vaccine adjuvant forms a "storage library" at an injection site to store antigens and slowly release the antigens, and the purpose of long-time continuous stimulation of the immune system in the body is achieved.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

This invention relates to the field of irregular antibody detection technology, specifically to an automated washing microfluidic chip for irregular antibody detection. The chip includes a chip body, a membrane, and a detection component comprising a sample application chamber and a detection chamber arranged sequentially away from the center of rotation. The sample application chamber and the detection chamber are connected by a washing channel. The detection component is pre-filled with a washing solution that can fill the detection chamber and the washing channel under centrifugation. The washing solution contains anti-human immunoglobulin that reacts with erythrocyte antigen-antibody complexes. The specific gravity of the washing solution is configured to be greater than the specific gravity of the sample to be tested but less than the specific gravity of the erythrocyte antigen. This configuration solves the problems of cumbersome procedures, excessive time consumption, high operator dependence, and difficulty in standardization caused by multiple manual washing steps required in traditional test tube methods for detecting irregular antibodies. It effectively ensures detection sensitivity and accuracy and reduces the false negative rate.

The application discloses a recombinant adenovirus vector tumor vaccine and a preparation method and application thereof, wherein the antigen coded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of more than two antigen peptide epitopes of KRAS protein. The recombinant adenovirus vector tumor vaccine of the application codes multiple KRAS tumor-specific antigen peptides, and has a good killing effect on KRAS mutation-driven tumors, especially lung tumors. The vaccine can be inhaled in a form of atomization, injected into muscles first and then inhaled in a form of atomization, inhaled in a form of atomization first and then injected into muscles, injected into muscles, or simultaneously injected into muscles and administered in a form of atomization. After atomization, the vaccine can be inhaled through a nasal cavity or an oral cavity to reach the lungs, generate an anti-tumor protective immune response on the respiratory tract, the lungs and the whole body, and enhance the utilization rate and the treatment effect of the vaccine.

A method and compositions of matter for treating or preventing an auto-immune disorder or immune response in a patient, that includes providing a therapeutic dose to the patient of a substituted indole compound having at least one substitution, wherein the substituted indole compound has only one thiol group, and wherein the ring the thiol group is attached to only contains one N or O atom.

This invention relates to an immune-enhancing polypeptide and its applications, specifically providing an immune-enhancing polypeptide, wherein the polypeptide is the N-terminal amino acid sequence of pyroptosis-associated protein GSDMD from position 1 to 500 or a truncated sequence thereof. The immune-enhancing polypeptide described herein can induce a stronger immune response and can simultaneously satisfy multiple antigen loading formats.

The present disclosure provides nucleic acid molecules (e.g., a plasmid or vector) comprising a nucleic acid sequence encoding a bicistronic or multicistronic LAMP Construct comprising specific fragments of the LAMP luminal domain and an antigenic domain heterologous to the LAMP protein to provide at least one antigen for priming an immune response, wherein the antigen expressed by the Construct is optionally processed and presented to MHC class II molecules, and also a nucleic acid sequence encoding an immune response enhancing polypeptide that is optionally secreted from a host cell. The nucleic acid molecules can be used, for example, for the treatment of disease and in particular, allergies, infectious disease, diabetes, hyperproliferative disorders and / or cancer.

The present invention provides a group of compounds for the sequestration of Adeno-associated virus (AAV) and adenovirus (AdV) neutralizing antibodies (NAbs) in a patient. The compounds comprise an inert backbone conjugated with at least one recombinant peptide comprising an epitope. The epitope is a conserved epitope that is targeted by human anti-AAV or anti-AdV NAbs. The backbone where the conserved epitope is conjugated to is a poly-lysine (PLys) or poly-acrylamide (PAA) backbone, among others. Also provided is a pharmaceutical composition comprising this type of compounds, as well as a method for use to treat an individual to inhibit the immune reaction against an AAV or AdV-based therapy. It is also possible to use synthetic compounds for an in vitro detection of anti-AAV or anti-AdV NAbs in a sample.

Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin ανβ6 in a specimen.

This invention discloses a bubble-soluble microneedle patch for delivering mRNA, its preparation method, and its applications. The bubble-soluble microneedle patch includes a base and an array of soluble microneedles on the base, with bubbles present at the connection between the base and the soluble microneedles. The soluble microneedles comprise a soluble polymer material and lipid nanoparticles carrying mRNA, providing a novel delivery method for mRNA. The bubble-soluble microneedle patch provided by this invention solves the problem of lipid nanoparticle accumulation in the liver and subsequent side effects caused by traditional intramuscular injection of mRNA vaccines. It also solves the problem of low-temperature storage of mRNA vaccines, allowing the resulting soluble microneedle patch to be stored at room temperature. It can efficiently deliver mRNA to lymphatic organs and to the subcutaneous dermis rich in antigen-presenting cells (APCs), thereby inducing a strong immune response in vivo.

This invention belongs to the field of biosensors and electrochemiluminescence (ECL) detection technology, and discloses an electrochemiluminescence sensor based on a UiO-67 confined single-site iridium complex, its construction method, and applications. The system uses zirconium-based metal-organic framework (MOF) material UiO-67 as a carrier, and iridium(III) bridging compounds are bonded through coordination to construct an in-situ Ir@UiO-67 nano-signal probe with high ECL activity. This probe is labeled with P-tau 181 secondary antibody to obtain an Ab2-Ir@UiO-67 complex. Simultaneously, a boron-doped diamond electrode modified with a gold film is used as the substrate electrode, and P-tau 181 primary antibody is immobilized to construct a specific recognition interface. A highly sensitive electrochemiluminescence sensing platform is then assembled via a sandwich immunoassay. This invention improves upon the bottleneck problems of poor water solubility and easy aggregation and quenching of traditional iridium complexes through MOF coordination anchoring and pore spatial confinement effects, achieving ultrasensitive quantitative detection of P-tau 181. It exhibits excellent specificity, reproducibility and stability in plasma samples.

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.

This invention discloses a type B influenza virus T4 peptide that can induce cellular immune responses and its applications, belonging to the fields of immunotherapy and immunoassay technology. The immunogenicity of this long peptide (SEQ ID NO.1, named T4) was verified in 21 volunteers using ELISpot assay. Results showed that T4 was positive in 5 individuals, with a positive rate of 23.81%. ELISpot assay of human PBMCs (IFN-γ secretory cells) showed that T4 induced an immune response of up to 3060 SFCs / 10 in the population. 6 PBMC. Therefore, this peptide has good immunogenicity and universality in the population, and can be used as a specific detection peptide for monitoring cellular immune levels. At the same time, this peptide can effectively activate the T cell immune response in the population, and has the potential to be used as a candidate vaccine epitope peptide for the design of novel vaccines.

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

The present invention relates to the technical field of medical and cosmetic raw materials, and particularly relates to a triple-helix structure collagen fleece membrane, a preparation method therefor, and use thereof. In the present invention, without involving a chemical crosslinking agent, vacuum freeze-drying treatment is adopted, and the prepared triple-helix structure collagen fleece membrane possesses excellent mechanical properties and high production efficiency. Excellent biocompatibility ensures that the triple-helix structure collagen fleece membrane, when used in the preparation of medicines or cosmetics, does not cause immune reactions such as skin inflammation.

The present application relates to a kind of recombinant bacillus subtilis of PRRSV ER protein on spore surface display, construction method and application.The recombinant bacillus subtilis is by genetic engineering method, with integrated plasmid pDG364 as foundation, constructs a recombinant vector with spore coat protein CotB as anchor protein, surface display PRRSV ER protein, is obtained by chemical transformation method with the recombinant vector is transformed into wild type bacillus subtilis 168, it has genetic stability, and will not be lost in the process of passage.The antigen protein is directly displayed on the spore surface of the bacterium, without crushing, can be directly mixed with material or through drinking water immunization animal, avoid the cumbersome process of large-scale injection.Benefiting from the good stress resistance of spore, the bacterium is easy to preserve and transport, significantly reduce cost.The bacterium can induce specific immune response, which provides a new way for the prevention and treatment of PRRSV, suitable for the development of commercial vaccine.

Peptide fragments of Amuc_1100* and uses thereof are disclosed. The peptides are shown to be ligands that activate TLR2 and are useful in the treatment of obesity and related diseases or disorders. The peptides of the invention are further useful in the treatment of small intestinal cancer, in the promotion of immune responses, and in intestinal epithelial barrier dysfunction.

This invention relates to the preparation and application of a recombinant bivalent vaccine for porcine reproductive and respiratory syndrome (PRRS). The recombinant bivalent PRRS vaccine is prepared using gene recombination technology. The genes encoding the fusion proteins of the major structural proteins GP2, GP3, GP4, GP5, and M protein B-cell epitopes of PRRS-like strains NADC30 and NADC34, as well as their recombinant strains, are cloned into a vector, transformed into host bacteria, and prepared through processes such as fermentation, purification, mixing, and emulsification. Animal experiments show that the recombinant bivalent PRRS vaccine can effectively improve the humoral and cellular immune responses in target animals.